FDA Mulls Clearing Abilify Rival Based On Single Trial
The U.S. Food and Drug Administration on Wednesday disclosed that it is considering whether to approve a competing version of blockbuster antipsychotic Abilify on the basis of a single clinical trial,...To view the full article, register now.
Already a subscriber? Click here to view full article